Market Cap
$177.8M
MDWD
MediWound Ltd.
$13.52 ▼ -0.59%
Prev close $13.60Market cap$177.8M
ConsensusStrong Buy
12-mo target$30.67 (+126.8%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders) Biotech & Drug Discovery
Snapshot
The big-picture read on MDWD right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (92%)
Insider Activity
$142.7K buy / $82.1K sell
Insider Net $
$60.6K
Social Sentiment
50° Neutral
SEC Reports
4
Press Releases
2
Price chart 30d +2.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 22, 2026 contract
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-St
Sep 1, 2026 Insider
Rubinstein Samuel bought 525 shares
Director @ $12.62 ($6.6K)
Sep 1, 2026 Insider
Rubinstein Samuel sold 525 shares
Director @ $12.72 ($6.7K)
Aug 27, 2026 Insider
Jun 2, 2026 SEC Hess Shmuel sold 1,979 shares
COO & Chief Commercial Officer @ $13.13 ($26.0K)
Two MediWound directors made open-market purchases totaling $27K over a 4-day window. While the dollar amount is small r
CLUSTER — Impact 4/10
MediWound reported Q1 2026 revenue of $1.5M (down 63% YoY from $4.0M) and a GAAP net loss of $0.23 per share (vs. -$0.07
PRESS-RELEASE — Impact 6/10
MediWound announced it will release Q1 2026 financial results on May 27, 2026, with a conference call to follow. No fina
PRESS-RELEASE — Impact 2/10
MediWound Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, disclosing audited fina
Impact 3/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| May 28, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% |
Price targets
Where 6 covering analysts think MDWD trades over the next 12 months.
$30.67 +126.8% upside Strong Buy
Current$13.52 Low$25.00 Median$30.00 High$36.00 6 analysts
$25.00$36.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 1 bullish, 1 bearish, 0 mixed, 2 neutral · avg impact 3.5/10.Plus 2 press releases.
BULLISHCLUSTER4/10
Two MediWound directors made open-market purchases totaling $27K over a 4-day window. While the doll
Jun 2, 2026
BEARISHPRESS-RELEASE6/10
MediWound reported Q1 2026 revenue of $1.5M (down 63% YoY from $4.0M) and a GAAP net loss of $0.23 p
May 27, 2026
NEUTRALPRESS-RELEASE2/10
MediWound announced it will release Q1 2026 financial results on May 27, 2026, with a conference cal
May 7, 2026
NEUTRAL6-K2/10
MediWound Ltd. (MDWD) has issued a 6-K filing to announce its 2026 Annual General Meeting of Shareho
Mar 30, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 22, 2026
contract
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®
Sep 2, 2026
other
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference
Aug 13, 2026
earnings_calendar
MDWD Q2 2026 Earnings Scheduled — 2026-08-13
May 27, 2026
earnings
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected </
May 27, 2026
earnings_calendar
MDWD Q1 2026 Earnings Scheduled — 2026-05-27
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.73 | $-0.92–$-0.62 | -202.5% | +0.0% | 2↑ 3↓ | $0.0B | 5 |
| Next Q | $-0.66 | $-0.79–$-0.52 | -17.1% | +0.0% | 2↑ 3↓ | $0.0B | 5 |
| Current FY | $-2.23 | $-2.71–$-1.98 | -6.2% | +0.0% | 3↑ 1↓ | $0.0B | 5 |
| Next FY | $-2.29 | $-2.80–$-2.00 | -2.7% | +0.0% | 1↑ 4↓ | $0.0B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.726 | — |
| 7d ago | $-0.726 | — |
| 30d ago | $-0.726 | — |
| 60d ago | $-0.706 | -0.020 |
| 90d ago | $-0.706 | -0.020 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 13 transactions. Net $60.6K — $142.7K bought, $82.1K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Rubinstein Samuel | Director | BUY | 525 | $12.62 | $6.6K |
| Sep 1, 2026 | Rubinstein Samuel | Director | SELL | 525 | $12.72 | $6.7K |
| Aug 27, 2026 | Hess Shmuel | COO & Chief Commercial Officer | SELL | 1,979 | $13.13 | $26.0K |
| Aug 27, 2026 | Hess Shmuel | COO & Chief Commercial Officer | EXERCISE | 11,000 | — | — |
| Aug 27, 2026 | Hess Shmuel | COO & Chief Commercial Officer | SELL | 1,979 | $12.72 | $25.2K |
| Aug 26, 2026 | Hess Shmuel | COO & Chief Commercial Officer | SELL | 1,865 | $13.00 | $24.2K |
| Aug 26, 2026 | Hess Shmuel | COO & Chief Commercial Officer | EXERCISE | 5,000 | — | — |
| Jun 3, 2026 | SHAMIR NACHUM | Director | BUY | 175 | $13.98 | $2.4K |
| Jun 3, 2026 | SHAMIR NACHUM | Director | BUY | 5,825 | $14.00 | $81.5K |
| Jun 1, 2026 | Fox David Morton | Director | BUY | 1,730 | $14.23 | $24.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MDWD.
Shares short
1,813,385
Settlement Sep 15, 2026
Change vs prior
+11.4%
Semi-monthly cycle
Days to cover
14.4
At avg daily volume
Of shares outstanding
≈14.1%
Estimate — not % of float
All MDWD filing & press-release reports (6)
- CLUSTER reportJun 2, 2026
- PRESS-RELEASE reportMay 27, 2026
- PRESS-RELEASE reportMay 7, 2026
- 6-K reportMar 30, 2026
- PRESS-RELEASE reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026